COMMUNIQUÉS West-GlobeNewswire

Best BPC-157 Oral Supplements: ProHealth's Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026
24/12/2025
36-Year Company's Oral Capsule Format vs. Injectable BPC-157: Third-Party Lab Testing, Bioavailability Questions, and Regulatory Status Examined CARPINTERIA, Dec. 23, 2025 (GLOBE NEWSWIRE) -- This article contains [...]
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
24/12/2025
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; [...]
Best Peptides for Muscle Growth: Prescription Sermorelin Access, Injectable vs. Dissolving Tablets, and Realistic Expectations
24/12/2025
Platform Analysis: Injectable vs. Dissolving Tablet Formats, Prescription Requirements, Monthly Subscription Costs, and Timeline Expectations for Growth Hormone Secretagogue Therapy AUSTIN, Dec. 23, 2025 (GLOBE NEWSWIRE [...]
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
23/12/2025
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment [...]
Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche
23/12/2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) ( [...]
Organogenesis Announces Initiation of Biologics License Application for ReNu®
23/12/2025
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative [...]
SeaStar Medical Announces 1-for-10 Reverse Split
23/12/2025
DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
23/12/2025
RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and [...]
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
23/12/2025
Seasoned executive brings four decades of finance, capital markets, and life sciences experience DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical [...]
West Hollywood Orthodontist Launches Free 'Student Airway Baseline' Screenings After Research Links Sleep-Disordered Breathing to Academic Struggles
23/12/2025
Harvard-trained orthodontist offers complimentary 15-minute airway analysis to help identify hidden causes of childhood focus problems LOS ANGELES, Dec. 23, 2025 (GLOBE NEWSWIRE) -- McComb Orthodontics , a specialty [...]
Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan
23/12/2025
Ghent, Belgium, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan PRESS RELEASE REGULATED INFORMATION / INSIDE INFORMATION 23 December 2025, 6:30 [...]
Singlera Genomics Signs European Distribution and Research Agreement with Pure Medical for Cancer Detection Products
23/12/2025
LA JOLLA, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the development and application of novel DNA methylation technologies to genetic diagnosis, today announced that it has entered [...]
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
23/12/2025
ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D ( [...]
BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference
23/12/2025
MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
MannKind Shares FUROSCIX® Business Updates
23/12/2025
FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE [...]
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
23/12/2025
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure. The $300 rate will apply to claims approved and paid by Medicare with [...]
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
23/12/2025
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores Entera's [...]
EMJX Expands Risk-Intelligence Framework with Prediction-Market Probability Data to Enhance Treasury Stress Detection
23/12/2025
NORTH PALM BEACH, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies (“EMJX”), its digital-asset treasury operating platform, today [...]
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
23/12/2025
Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology [...]

Pages